Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Heart Failure 1Cardiotoxicity 1Breast Neoplasms 1

Interventions

Fulvestrant 34Specimen Handling 31Letrozole 30Paclitaxel 23pembrolizumab 19Carboplatin 19ribociclib 18exemestane 18Capecitabine 17Trastuzumab 16Tamoxifen 16Magnetic Resonance Spectroscopy 16palbociclib 15Anastrozole 15Biopsy 14trastuzumab deruxtecan 13abemaciclib 13pertuzumab 11Radiotherapy 11Cyclophosphamide 9inavolisib 8elacestrant 8olaparib 7Taxes 7Standard of Care 7Radiation 7Mastectomy, Segmental 7Goserelin 7130-nm albumin-bound paclitaxel 7giredestrant 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × empagliflozin × 30 days × Clear all
NCT06844669 2026-05-13

HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy

Washington University School of Medicine

Phase 2 Terminated
7 enrolled
Breast

Breast Neoplasms, Heart Failure, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡